Expression of cyclooxygenase-1 in epithelial ovarian cancer: A clinicopathological study

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 4, 2008, Pages 757-762

  Khunnarong, Jakkapan ^a   Tangjitgamol, Siriwan ^a   Manusirivithaya, Sumonmal ^a   Suekwattana, Pacheun ^a   Leelahakorn, Surawute ^a  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

Author keywords

Clinicopathological factors; Cyclooxygenase 1; Epithelial ovarian cancer

Indexed keywords

CYCLOOXYGENASE 1; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOMA; COHORT ANALYSIS; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; OBSERVER VARIATION; OVARY TUMOR; PATHOLOGY; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; THAILAND; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; CARCINOMA; COHORT STUDIES; CYCLOOXYGENASE 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBSERVER VARIATION; OVARIAN NEOPLASMS; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THAILAND; TUMOR MARKERS, BIOLOGICAL;

EID: 66149149850     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev, 22, 255-88.
2. Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ (2005). Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg, 92, 429-34.
3. Crofford LJ (1997). COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol, 24 (Suppl 49), 15-9.
4. Davis BJ, Lennard DE, Lee CA (1999). Anovulation in cyclooxygenase-2 deficiency mice is restored by prostaglandin E2 and interleukin 1b. Endocrinology, 140, 2685-95.
5. Daikoku T, Wang D, Tranguch S, et al (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res, 65, 3735-44.
6. Denkert C, Kobel M, Pest S, et al (2002). Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol, 160, 893-903.
7. Gasparini G, Longo R, Sarmiento R, Morabito A (2003). Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol, 4, 605-15.
8. Gupta RA, Tejada LV, Tong BJ, et al (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res, 63, 906-11.
9. Hwang D, Scollard D, Byrne J (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst, 90, 455-60.
10. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30.
11. Kino Y, Kojima F, Kiguchi K, et al (2005). Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids, 73, 103-11.
12. Koki AT, Masferrer JL (2002). Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control, 9 (2 Suppl), 28-35.
13. Li S, Miner K, Fannin R, Barrett JC, Davis BJ (2004). Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol, 92, 622-7.
14. Mantel N (1996). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70.
15. Ness RB, Cottreau C (1999). Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst, 91, 1459-67.
16. Ness RB, Grisso JA, Cottreau C, et al (2000). Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology, 11, 111-7.
17. NIH Consensus Development Panel on Ovarian Cancer (1995). NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. JAMA, 273, 491-7.
18. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
19. Pecorelli S, Odicino F, Maisonneuve P (1998). Carcinoma of ovary. Annual report on the results of treatment of gynaecologic cancer, vol 23. International Federation of Gynecology and Obstetrics. J Epidemiol Biostat, 3, 75-102.
20. Riman T, Nilsson S, Persson IR (2004). Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand, 83, 783-95.
21. Ristimaki A, Honkanen N, Jankata H (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res, 57, 1276-80.
22. Seo SS, Song YS, Kang D, et al (2004). Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular marker in epithelial ovarian cancer. Gynecol Oncol, 92, 927-35.
23. Tsujii M, Kawano S, Tsuji S (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705-16.
24. Urick ME, Johnson PA (2006). Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer. Gynecol Oncol, 103, 673-8.
25. Vane JR, Bakhle YS, Botting RM (1998). Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 38, 97-120.
26. van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ATM (1989). Predictability of the survival of patients with ovarian cancer. J Clin Oncol, 7, 769-73.
27. Whittemore AS (1994). Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol, 55, S15-9.
28. Wolff H, Saukkonen K, Anttila S (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res, 58, 4997-5001.
29. Zimmermann KC, Sarbia M, Weber AA (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res, 59, 198-204.